Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jan;12(1):57-70.
doi: 10.1586/erv.12.134.

The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches

Iana H Haralambieva  1 , Inna G Ovsyannikova, V Shane Pankratz, Richard B Kennedy, Robert M Jacobson, Gregory A Poland
Affiliations
Review

The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches

Iana H Haralambieva et al. Expert Rev Vaccines. 2013 Jan.

Abstract

The live-attenuated measles vaccine is effective, but measles outbreaks still occur in vaccinated populations. This warrants elucidation of the determinants of measles vaccine-induced protective immunity. Interindividual variability in markers of measles vaccine-induced immunity, including neutralizing antibody levels, is regulated in part by host genetic factor variations. This review summarizes recent advances in our understanding of measles vaccine immunogenetics relative to the perspective of developing better measles vaccines. Important genetic regulators of measles vaccine-induced immunity, such as HLA class I and HLA class II genotypes, single nucleotide polymorphisms in cytokine/cytokine receptor genes (IL12B, IL12RB1, IL2, IL10) and the cell surface measles virus receptor CD46 gene, have been identified and independently replicated. New technologies present many opportunities for identification of novel genetic signatures and genetic architectures. These findings help explain a variety of immune response-related phenotypes and promote a new paradigm of 'vaccinomics' for novel vaccine development.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Simons E, Ferrari M, Fricks J, et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet. 2012;379(9832):2173–2178. - PubMed
    1. MMWR. Measles – United States, January–May 20, 2011. MMWR Morb Mortal Wkly Rep. 2011;20:666–668. - PubMed
    1. MMWR. Measles – United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:253–257. - PubMed
    1. Chen SY, Anderson S, Kutty PK, et al. Health care-associated measles outbreak in the United States after an importation: challenges and economic impact. J Infect Dis. 2011;203(11):1517–1525. - PubMed
    1. Sanders R, Dabbagh A, Featherstone D. Risk analysis for measles reintroduction after global certification of eradication. J Infect Dis. 2011;204(Suppl 1):S71–S77. - PubMed

Websites

    1. World Health Organization. [Accessed 16 July 2012];Measles Fact Sheet No. 286. 2011 www.who.int/mediacentre/factsheets/fs286/en.
    1. World Health Organization. [Accessed 16 July 2012];Measles Outbreaks in Europe. 2011 www.who.int/csr/don/2011_04_21/en/index.html.
    1. World Health Organization. [Accessed 12 October 2012];Global Immunization Vision and Strategy. 2011 www.who.int/immunization/givs/en/index.html.
    1. WHO. Report of a meeting on research related to measles control and elimination. WHO Department of Vaccines and Biologicals; Geneva, Switzerland: 2000. [Accessed 12 October 2012]. www.who.int/vaccines-documents/DocsPDF00/www545.pdf.

Publication types